A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03413410|
Recruitment Status : Recruiting
First Posted : January 29, 2018
Last Update Posted : January 29, 2018
|Condition or disease||Intervention/treatment||Phase|
|ACS - Acute Coronary Syndrome||Drug: Metoprolol||Not Applicable|
Acute coronary syndrome(ACS) is one of the main manifestations of cardiovascular disease and one of the main causes for hospitalization in adults.
Previous studies showed that β-receptor blockers can reduce ACS patients' cardiovascular risk in both acute phase and secondary prevention. We summarized the metoprolol optimal dosing pathway based on Chinese and foreign guidelines as well as Chinese clinical practice.
Primary endpoint is the percentage of patients achieving target dose at time of discharge.
Secondary endpoints are the mean HR & BP at discharge and during the follow up period of the Patients who have achieved target dose at discharge.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome|
|Actual Study Start Date :||December 20, 2017|
|Estimated Primary Completion Date :||July 30, 2019|
|Estimated Study Completion Date :||July 30, 2020|
Experimental: Metoprolol interventional group
This is a multi-center, prospective, open label, single-arm interventional study.
Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study.
Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
- percentage of patients achieving target dose [ Time Frame: 1 month ]The percentage of patients achieving target dose of 95mg/d at the time of discharge
- mean heart rate [ Time Frame: 1 month ]The mean HR after achieving target dose
- mean blood pressure [ Time Frame: 1 month ]The mean BP after achieving target dose
- percentage of patients who experienced bradycardia with symptoms [ Time Frame: 1 month ]The percentage of patients who experienced bradycardia with symptoms during hospitalization and for 1 month after discharge, respectively
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413410
|Contact: Dandan Li, MDfirstname.lastname@example.org|
|The General Hospital of PLA||Recruiting|
|Beijing, China, 100853|
|Contact: Dandan Li, MD +8613810545564 email@example.com|
|Principal Investigator:||Yundai Chen, MD||The General Hospital of PLA|